Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

OBJECTIVE: To compare the effectiveness of rituximab (RTX) or a second anti–tumor necrosis factor (anti-TNF) therapy in rheumatoid arthritis (RA) patients who had failed their first anti-TNF and switched to either RTX or a second anti-TNF, in routine clinical practice. METHODS: RA patients were regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Moetaza M, Hyrich, Kimme L, Lunt, Mark, Watson, Kath D, Symmons, Deborah P M, Ashcroft, Darren M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2012
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492906/
https://www.ncbi.nlm.nih.gov/pubmed/22422731
http://dx.doi.org/10.1002/acr.21663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492906/
https://www.ncbi.nlm.nih.gov/pubmed/22422731
http://dx.doi.org/10.1002/acr.21663

Ejemplares similares